Drug Profile
SBI 087
Alternative Names: PF-05230895; PF-5230895; SBI-087Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Trubion Pharmaceuticals
- Developer Emergent BioSolutions; Pfizer
- Class Anti-inflammatories; Antirheumatics; Proteins
- Mechanism of Action CD20 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 10 May 2012 Discontinued - Phase-II for Rheumatoid arthritis in Argentina (SC)
- 10 May 2012 Discontinued - Phase-I for Rheumatoid arthritis in Canada (IV)
- 10 May 2012 Discontinued - Phase-I for Rheumatoid arthritis in Japan (IV)